2-(3,3-dimethylpyrrolidin-1-yl)ethanamine | 3437-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(3,3-dimethylpyrrolidin-1-yl)ethanamine
• 英文别名: N-(2-Aminoethyl)-3,3-dimethylpyrrolidin；2-(3,3-dimethyl-pyrrolidin-1-yl)-ethylamine；2-(3,3-Dimethylpyrrolidin-1-yl)ethan-1-amine
• CAS: 3437-32-9
• 化学式: C₈H₁₈N₂
• mdl: MFCD19206010
• 分子量: 142.244
• InChiKey: UOLFIRYVZLZHDX-UHFFFAOYSA-N

物化性质

• 沸点：
  74 °C(Press: 12 Torr)
• 密度：
  0.892±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-((6-((1,3-dimethyl-1H-pyrazol-4-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)amino)-6-methylnicotinic acid 、 2-(3,3-dimethylpyrrolidin-1-yl)ethanamine 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以44 %的产率得到5-((6-((1,3-dimethyl-1H-pyrazol-4-yl)amino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)amino)-N-(2-(3,3-dimethylpyrrolidin-1-yl)ethyl)-6-methylnicotinamide
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  公开号：

  WO2023007009A1
• 作为产物：
  描述：

  2-(3,3-dimethylpyrrolidin-1-yl)acetonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-(3,3-dimethylpyrrolidin-1-yl)ethanamine
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  公开号：

  WO2023007009A1

文献信息

• [EN] SILICON INCORPORATED QUINOLINES WITH ANTI-MALARIAL AND ANTI-TOXOPLASMOSIS ACTIVITY<br/>[FR] QUINOLÉINES À SILICIUM INCORPORÉ PRÉSENTANT UNE ACTIVITÉ ANTI-PALUDÉENNE ET ANTI-TOXOPLASMOSE
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2017168448A1

  公开（公告）日：2017-10-05

  The present invention discloses a silicon incorporated quinoline of formula (I) wherein, X, Y, A, R1 and R2 are as described. The present invention further discloses a process for the preparation of silicon incorporated quinolines of formula I; a pharmaceutical composition comprising silicon incorporated quinolines of formula (I) or pharmaceutically acceptable salt thereof. The present invention also discloses a method for treating diseases caused by Plasmodium falciparum or other coccidian parasites using the silicon incorporated quinolines of formula I or pharmaceutically acceptable salt thereof.

  本发明公开了一种具有化学式（I）的硅掺杂喹啉，其中，X、Y、A、R1和R2如所述。本发明还公开了一种制备化学式I的硅掺杂喹啉的方法；一种包含化学式（I）的硅掺杂喹啉或其药用可接受盐的药物组合物。本发明还公开了一种使用化学式I的硅掺杂喹啉或其药用可接受盐治疗由疟原虫或其他球虫寄生虫引起的疾病的方法。
• [EN] PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS<br/>[FR] PYRAZOLOTHIAZOLE CARBOXAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2022136509A1

  公开（公告）日：2022-06-30

  The disclosure is directed to compounds of formula (I),and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  本公开涉及式(I)的化合物及其药学上可接受的盐。还描述了包含式(I)化合物的制药组合物，以及它们的使用和制备方法。